Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

15.9%

771 terminated/withdrawn out of 4845 trials

Success Rate

81.7%

-4.8% vs industry average

Late-Stage Pipeline

26%

1238 trials in Phase 3/4

Results Transparency

63%

2164 of 3452 completed trials have results

Key Signals

244 recruiting2164 with results630 terminated141 withdrawn

Enrollment Performance

Analytics

Phase 1
1396(34.8%)
Phase 2
1086(27.1%)
Phase 3
792(19.7%)
Phase 4
446(11.1%)
N/A
273(6.8%)
Early Phase 1
20(0.5%)
4013Total
Phase 1(1396)
Phase 2(1086)
Phase 3(792)
Phase 4(446)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4845)

Showing 20 of 4845 trials
NCT06897202Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

Role: lead

NCT06436703Phase 1Completed

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

Role: lead

NCT00329043Phase 2Active Not Recruiting

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Role: collaborator

NCT00715442Phase 2Active Not Recruiting

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Role: collaborator

NCT07392892Phase 2Recruiting

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Role: lead

NCT06439524Phase 3Recruiting

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

Role: collaborator

NCT07578649Phase 3Not Yet Recruiting

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

Role: lead

NCT04607421Phase 3Active Not Recruiting

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Role: lead

NCT07311850Phase 3Recruiting

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Role: lead

NCT06462235Phase 2Recruiting

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Role: lead

NCT05748171Phase 2Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Role: lead

NCT05639647Phase 2Recruiting

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Role: lead

NCT04155541Completed

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

Role: lead

NCT07637578Phase 2Not Yet Recruiting

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT07578636Phase 1Recruiting

A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults

Role: lead

NCT06989437Phase 2Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Role: lead

NCT07575932Phase 2Recruiting

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Role: lead

NCT05538130Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Role: lead

NCT05407805Completed

A Study to Learn About Sickle Cell Disease In Adult Patients

Role: lead

NCT07486921Phase 2Recruiting

Etrasimod as Prevention of Pouchitis

Role: collaborator